Module 1: Regulatory Considerations for the Development of CNS/Neurology Therapeutics
Recorded On: 02/15/2024
According to 21 CFR Part 312.23 (a)(8) of the US regulations, sufficient information derived from nonclinical pharmacology and toxicology studies is needed in order to support the decision that a clinical trial in human subjects is reasonably safe and scientifically feasible to conduct. The data resulting from the nonclinical studies should support scientific proof-of-principle and safety for the administration of the investigational product in the specified clinical population. In addition, nonclinical studies help guide the design of certain elements of a clinical trial. The development of cell and gene therapies for neurological indications over recent decades has demonstrated the potential clinical benefits of these therapies for this heterogeneous group of disorders. However, there remain significant questions, including the risks associated with these products that are not understood. Thus, a comprehensive nonclinical characterization of novel cell and gene therapy products and their associated risks are critical for the safe conduct of future clinical trials. This presentation will provide a general overview of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products (OTP), the existing regulatory framework, including avenues for interactive communications, and resources to guide stakeholders in the nonclinical assessment of the safety and activity of cell and gene therapy products for neurological indications.
Mondona McCann, PhD
Pharmacology/Toxicology Reviewer
US FDA
Dr. Mondona McCann is a Pharmacology/Toxicology reviewer in the U.S. Food and Drug Administration (FDA)’s Center for Biologics Evaluation and Research (CBER)’s Office of Therapeutic Products. She received her PhD in neuroscience from Georgetown University; her thesis research investigated the impact of organochlorine environmental toxicants on astrocytic function and metabolism. Following her graduate studies, Dr. McCann completed her post-doctoral training at the FDA where she conducted research on the efficacy and safety of IL13Rα2 CAR T cell therapy for glioblastoma and pancreatic cancer. At the completion of her fellowship, Dr. McCann joined the Office of Pharmacology and Toxicology, where she now focuses on the review of nonclinical toxicology and pharmacology data to support the safety of a variety of products including cell and gene therapies, tissue engineered products, and tumor vaccines.